Anti-ApoA-1 IgG serum levels predict worse poststroke outcomes.
Federico CarboneNathalie SattaFabrizio MontecuccoJulien VirziFabienne BurgerAline RothGloria RoversiCarmine TamborinoIlaria CasettaSilva SeraceniAlessandro TrentiniMarina PadroniFranco DallegriPatrice H LaliveFrançois MachEnrico FainardiNicolas VuilleumierPublished in: European journal of clinical investigation (2017)
Anti-ApoA-1 IgG serum levels at AIS onset are associated with poorer clinical recovery and worse brain lesion volume 3 months after AIS. These observations could be partly explained by the deleterious effect of anti-ApoA-1 IgG on human brain cell survival in vitro and may have clinical implication in the prediction of poor outcome in AIS.